Introduction
We next sought to confirm our findings in an independent Apc-driven CRC model. Apc Min mice carry a 83 heterozygous nonsense mutation at codon 850 of Apc and develop intestinal tumors following spontaneous loss 84 of the wildtype allele (18). We treated tumor-bearing 15-20 week-old Apc Min mice for one week with G007-LK 85 (30mg/kg, QD) and measured tumor response on histological cross sections, as described above. Surprisingly, 86 and in contrast to what we observed in the TG-shApc model, Apc
Min tumors were completely insensitive to 87 G007-LK treatment. In fact, while adjacent normal intestine showed elevated Axin1 and decreased Lgr5 88 staining, confirming drug exposure (Supplementary Figure 1b- The difference in tumor response between these two Apc-driven models was striking, and in contrast to a recent 92 report by Tanaka et. al., which suggested that early truncating mutations in APC sensitize cell lines to TNKS 93 inhibition (19). To ensure this conflicting effect was not due to differences in in vivo tumor growth kinetics or 94 timing of treatment, we generated shApc and Apc Min intestinal organoids and treated them ex vivo for 3 days with 95 G007-LK (1µM). In support of our in vivo results, G007-LK-treated shApc organoids underwent rapid cell cycle 96 arrest, while Apc Min organoids maintained a proliferative phenotype ( Figure 1e ). RNA expression by quantitative 97
RT-PCR (qPCR) further confirmed that TNKS1/2 inhibition induced Krt20 and reduced Lgr5 in shApc 98 organoids, but had no effect in Apc Min cultures (Figure 1f ). Together, this data supports the notion that TNKS 99 inhibition can effectively promote tumor cell arrest in some contexts. 100
Although BrdU incorporation was significantly decreased in G007-LK-treated shApc tumors, the response was 101 less uniform than following genetic Apc restoration (Figure 1b) , raising the possibility that variable drug dose 102 or delivery may have impacted tumor response in some cases. Indeed, current TNKS inhibitors show limited 103 oral bioavailability and require daily or twice daily intraperitoneal or intratumoral delivery to achieve effective 104 TNKS blockade (16, 20) . In addition, in our hands, daily i.p. dosing also produced inflammatory adhesions on 105 the liver spleen and peritoneum, precluding increased or prolonged treatment (Supplementary Figure 1d) . To 106 achieve potent, constitutive TNKS blockade without the confounding issue of drug delivery we produced two 107 new transgenic strains (carrying independent tandem shRNAs) that enable dox-inducible silencing of Tnks1/2. 108
To do this we first screened a series of Tnks and Tnks2 miRE-based shRNAs using a fluorescent sensor 109 The in vivo data described above highlights that response to TNKS inhibition may be dependent on the genetic 131 context of the tumor. We sought to reconcile which model better reflects the biology and therapeutic response of 132 human CRC; therefore, we analyzed two independent clinical datasets (MSK-IMPACT colorectal and TCGA 133
PanCan colorectal cancer) for the type and frequency of APC mutations. Consistent with previous analyses 134
(1,2), APC mutations were present in 1231/1693 (73%) patient samples, with predominantly nonsense mutations 135 throughout the N-terminal half of the gene (Figure 3a) . Further examination of tumors with two identifiable 136 APC mutations revealed a striking selection for cancers carrying at least one truncating mutation within the 137 mutation cluster region (MCR) that spans amino acids ~1250-1580 (Figure 3b ). Moreover, cases in which only 138 one allele could be identified showed a further bias toward mutations in the MCR (Supplementary Figure 4a-b) . 139
These observations are consistent with previous analyses on an independent cohort (21), and strongly implies 140 that accurate genetic models of human CRC should harbor at least one MCR mutation in APC, more C-terminal 141 than either the Apc Min or Apc Flox alleles (Figure 3b ). 142
To engineer defined nonsense mutations both preceding and within the MCR, we used recently described 143 optimized base editing tools (22). We transfected wildtype C57Bl/6 intestinal organoids with the FNLS base 144 editing enzyme (22), and sgRNAs targeting codons Q884 (Apc which truncates APC after the armadillo repeats, but before the first set of 15 amino acid -catenin binding 147 repeats ( Figure 3c ). Truncation of Apc at Q1405, immediately after the second 20 amino acid repeat (20AAR), 148 removes a conserved 'catenin inhibitory domain' (CID) (Figure 3c ) that is thought to be critical for proper -149 and shApc organoids, as well as those with an activating missense mutation in serine 33 of Ctnnb1 (cat S33F ) 152 (Supplementary Figure 5b) ; this mutant protein cannot be phosphorylated at S33 by GSK3, and is therefore 153 independent of the DC. 154
All mutant organoids could be maintained in the absence of WNT/RSPO ligands, confirming cell intrinsic 155 constitutive activation of WNT signaling. To assess the response to TNKS inhibition, we treated each mutant 156 with G007-LK (1µM) for 7 days, and quantified cell survival by counting viable organoids. As expected, 157 cat S33F showed no change in morphology or viability following G007-LK treatment. Similarly, and consistent 158 with the lack of response in Apc Min cells, Apc Q884X organoids showed no response to G007-LK. In contrast, 159 Apc Q1405X and shApc organoids showed reduced crypt branching after 3 days, and were unable to survive 7 days 160 of G007-LK treatment (Figure 3d-e) . Importantly, the lack of response to TNKS inhibition in Apc Q884X and 161
Apc
Min cultures was not specific to these similar truncating alleles, as organoids carrying an even earlier 162 truncation, Apc 580 (generated from the Apc flox allele (27)), were also resistant to G007-LK treatment 163 (Supplementary Figure 6a) . Further, the effect was not specific to G007-LK, as we noted a similar genotype-164 dependent response with two independent TNKS inhibitors of different chemotypes: NVP656 (20) and XAV939 165 (6) (Supplementary Figure 6b) . 166
To gain insight into the molecular events underlying the genotype-dependent response to G007-LK, we 167 performed transcriptome profiling by RNAseq. Figure 7a) . More than 80% of the variance in gene expression between groups was 172 accounted for by PC1, which included a number of canonical WNT target genes, including Sox17, Nkd1, Wnt6, 173 and Prox1. In general, organoids with cat S33F mutations and early Apc truncations clustered together and had 174 higher WNT target gene expression, while Apc Q1405X and shApc organoids had lower WNT target induction, 175 albeit markedly higher than wildtype organoids (Supplementary Figure 7b) . Importantly, the transcriptome 176 analysis showed that organoids derived from Apc Min mice (Apc
L850X
) and those with a similar base editing-177 induced mutation (Apc , and wildtype organoids. Indeed, significant 181 gene expression changes (log2FC >2, adj. p-value <0.01) observed in wildtype cultures following treatment with 182 G007-LK (or RSPO1 withdrawal) were closely mirrored in shApc and Apc Q1405X organoids (Figure 3f ). In 183 contrast, few transcriptional changes were observed in G007-LK-treated Apc Min and Apc Q884X organoids (28 and 184 expression observed in cat S33F cultures (Table S1 ). The profound lack of response in cat S33F organoids strongly 186 suggests that the primary effect of TNKS inhibition is modulating DC activity via Axin1/2. 187
Gene set enrichment analysis (GSEA) of G007-LK-treated Apc Q1405X organoid transcriptomes identified an 188 upregulation of networks related to differentiated intestine function, such as protein and lipid metabolism, and a 189 decrease in cell cycle-related MYC and E2F targets (Figure 3g ). Conversely, MYC-related gene sets were 190 actually enriched in G007-LK-treated Apc Q884X cells (Supplementary Figure 7c) . As expected, G007-LK also 191 induced a significant decrease in WNT/catenin signaling in Apc Q1405X organoids (Figure 3h , Figure 12b- To determine whether established Apc Q1405X adenomas were sensitive to TNKS1/2 inhibition, we treated tumor-244 bearing 10-week-old Apc Q1405X/+ mice with G007-LK (30mg/kg, QD) or vehicle for 1 week. Histological 245 sections of G007-LK-treated intestinal tumors showed decreased nuclear to cytoplasmic ratio, nuclear 246 polarization, and a transition to differentiated villi-like structures (Figure 4g ; H&E). Consistent with this, 247 immunofluorescent staining showed reduced proliferation (Figure 4g 
Discussion

253
We previously reported that restoring Apc expression induces sustained tumor regression in CRC (4). Here, 254 using genetically defined animal models, organoids and human cell lines, we show that TNKS inhibition can re-255 engage the same endogenous tumor suppressive mechanism, but this molecular switch is highly dependent on 256 the specific Apc disruption. Tumor cells containing 'early' truncating mutations that eliminate all identified 257
Axin1/2 and -catenin motifs (e.g. Apc Min , Apc
Q884X
) do not respond to TNKS inhibition, yet those with an MCR 258 mutation can regulate -catenin and suppress oncogenic signaling in response to Axin1/2 stabilization. To our 259 knowledge, this is the first in vivo demonstration that subtle changes in CRC initiating genetic events can lead to 260 profound changes in response to targeted therapy and has implications for strategies that aim to modulate WNT 261 activity through the DC. 262
Consistent with previously published data (21) we observed in three independent datasets that the majority of 263
CRCs carry at least one nonsense mutation within the MCR (~1250-1580). This mutational pattern is 264 hypothesized to be a selection for mutations that enable oncogenic transformation yet retain partial -catenin 265 regulation, providing a 'just right' level of WNT activation (32-34). Interestingly, APC structure-function 266 studies in CRC cell lines and model organisms suggest that truncations at Q1405 that remove the 'Catenin 267 inhibitory domain' (CID) immediately after the second 20AAR, disrupt -catenin turnover, and thus drive high 268 levels of WNT activation (23, 24) . Consistent with this, our Apc Q1405X organoids, carrying the same truncating 269 allele, hyperactivate WNT signaling, and heterozygous Apc Q1405X/+ mice develop intestinal tumors with 100% 270 penetrance. However, in response to TNKS inhibition, Apc Q1405X can engage the DC to suppress hyperactive 271 WNT signaling; this response would not have been predicted from structure-function models. It is important to 272 note that while most human CRCs harbor both an early and late truncation, and our organoids were engineered 273 to carry two Apc Q1405X alleles, we observed that one of the biological replicates (replicate A) carried an 274 unexpected heterozygous deletion in one allele of Apc (Supplementary Figure 13a- 
c). While these cells express 275
only one truncated allele and show moderately higher baseline WNT activity, they have an identical response to 276 TNKS inhibition (Supplementary Figure 13d) , implying that the presence of one MCR truncated allele is 277 sufficient to engage the DC. 278
Given the importance of Apc interaction with -catenin and the DC, it is somewhat counter-intuitive that shApc 279 organoids and tumors show such robust WNT-suppression and differentiation responses to G007-LK, despite 280 extremely potent knockdown (Supplementary Figure 14) . We propose that the reason underlying the response of 281 shApc cells is the presence of a minimal residual amount of full-length Apc protein that can be detected in 282 complex with Axin1, but not in whole cell lysates (Supplementary Figure 14) . While the amount of Apc is 283 dramatically reduced, the residual protein contains all -catenin and Axin binding domains that allows it to 284 effectively engage the DC, and following Axin stabilization, drive WNT suppression. The observation that only 285 minimal full-length Apc protein is required for tumor suppression is consistent with our previously published 286 work, which showed that intestinal adenomas have a phenotypic response to genetic Apc restoration even before 287
Apc protein is detectable by western blot (4). 288
In all, these findings highlight that distinct mutations within the same gene can appear phenotypically similar 289 (hyperactive WNT), but have profoundly different biochemical responses to therapies targeting their mechanism 290 of action. This reinforces the need to create accurate and representative genetic models for understanding the 291 molecular events of disease and therapy response. 292
Our results contrast with recent in vitro work, which concluded that cells with early APC truncations are 293 uniquely sensitive to TNKS inhibition (19). In our experiments, WNT suppression correlated precisely with cell 294 cycle arrest and differentiation, consistent with the role of WNT as a driver of self-renewal and tumorigenesis. 295
In contrast, while almost all cell lines assessed by Tanaka et al. showed WNT suppression following TNKS 296 inhibition, most were not dependent on WNT for survival, and thus classified as resistant (19). We believe it is 297 likely that either the accumulation of specific oncogenic events, or prolonged in vitro culture relieved their 298 WNT dependence, confounding the correlation of TNKSi response and APC/WNT alterations. Indeed, one 299 recent study in lung adenocarcinoma demonstrated that WNT/RSPO-dependent 3D organoid cultures become 300
WNT-independent when cultured in 2D (35). Further, Lord and colleagues recently proposed that activating 301
Kras mutations may correlate with resistance to TNKS inhibitors (36). While the latter study did not ascribe a 302 specific mechanism to this possible interaction, it is consistent with multiple observations that concurrent 303 inhibition of classic oncogenic signaling pathways such as MAPK or AKT, enhances the response to TNKS 304 inhibition (12, 20, (37) (38) (39) . 305
While TNKS inhibition is unlikely to be used as a monotherapy for cancer treatment, it is perhaps worth 306 (re)considering its utility in patients with Familial Adenomatous Polyposis (FAP), that most commonly carry 307 heterozygous germline mutations in the MCR (40), and ultimately have few options other than surgical removal 308 of the colon. Our data imply that FAP-associated adenomas may respond to TNKS inhibitors, though a number 309 of issues of drug dose, bioavailability, and safety would need to be addressed before they could be considered a 310 viable option. 311
Understanding how specific oncogenic insults drive cell transformation and impact therapy response is a key 312 goal of precision oncology medicine. WNT pathway hyperactivation is a clear cancer driver in a number of 313 malignancies, including CRC (1, 4, 41, 42) , and has been suggested as an immune-modulator that may impact 314 response to checkpoint inhibitors (43-45). While WNT-targeted agents have yet to make significant progress in 315 clinical medicine, approaches to block WNT hyperactivation are of keen interest for cancer treatment. Defining 316 the genetic context/s in which they will be effective, as described here, is critical for the future development and 317 application of WNT-targeted therapeutics. Individual Tnks and Tnks2 shRNAs were cloned into MLPE vector at XhoI and EcoRI sites as previously 321 described (46). For tandem shRNA cloning, the destination vector containing shRNA #1 was digested with 322
EcoRI for 4 hours at 37˚C and incubated with CIP for 30 min at 37˚C. shRNA #2 was PCR amplified using 323 miRE-TX_For and miRE_EcoRI_Rev primers (Table S4) . Positive clones were identified by restriction digest 324 and validated by Sanger sequencing with mir30_seq primer (Table S4 ). Tandem shRNA cassettes were shuttled 325 into the col1A1 targeting vector (cTGME) following PCR amplification with miRE_XhoI_For and 326 miRE_EcoRI_Rev primers, and XhoI/EcoRI digest. For the shRNA sensor assay, shRNA target sequences 327 against Tnks and Tnks2 were arrayed, produced as a synthetic gBlock (IDT), and cloned into the 3'UTR of a 328 dTomato sensor vector (XhoI/ EcoRI). For Tnks or Tnks2 specific sensors, gBlocks with only Tnks or Tnks2 329 target sequences were designed and cloned as described above. sgRNA cloning into the vector LRT2B cloning 330 was performed as previously described (22,47). The shApc.2235E retroviral vector used to transduce organoids 331 was generated by Gibson cloning into the pMSCV-rtTA3-miRE vector. 332
Mutation detection by T7 assay 333
Cas9-induced mutations were detected using the T7 endonuclease I (NEB). Briefly, the target region 334 surrounding the expected mutation site was PCR-amplified using Herculase II (600675, Agilent Technologies). 335 PCR products were column purified (Qiagen) and subjected to a series of melt-anneal temperature cycles with 336 annealing temperatures gradually lowered in each successive cycle. T7 endonuclease I was then added to 337 selectively digest heteroduplex DNA. Digest products were visualized on a 2.5% agarose gel. were plated in a 6 well plate, and transduced with the LRT2B vector (Addgene #110854) containing either 360 hAPC.884 or FANCF.S1 control sgRNAs. Two days after transduction, cells were selected in Blasticidin S 361 (5g/ml) .3 x 10 4 LRT2B-transduced cells were plated for treatment with either DMSO or G007-LK 1M for 3 362 days for RNA and protein collection. Deidentified, patient-derived human colorectal cancer organoids 363 (WCM392 and WCM616; previously described (30)) were obtained from the Institute for Precision Medicine at 364
Weill Cornell Medicine. Organoids were cultured in Basal Media + B27, and treated with either DMSO or 365 G007-LK 1M for 3 days. 366
ES cell targeting 367
Embryonic Stem (ES) cells were maintained on irradiated feeders, C57Bl/6 cells were cultured 2i media and 368 KH2 cells were cultured in M15 media, both containing LIF as previously outlined (46). Cells were transfected 369 with targeting vector and CAGs-FlpE vector using a Lonza X-unit nucleofector with P3 buffer kit (Lonza 370 #V4XP-3032). Two days following transfections, cells were treated with media containing 150ug/ml 371 hygromycin and individual surviving clones were picked after 9-10 days of selection. Two days after clones 372 were picked hygromycin was removed from the media and cells were cultures in standard M15 thereafter. To 373 confirm single copy integration at the col1a1 locus we first validated expected integration by multiplex col1a1 374 PCR 3 , and second, confirmed the presence of a single GFP cassette using the Taqman copy number assay, 375 according to the manufacturer's instructions (Invitrogen). 376
Isolation and culture of intestinal organoids 377
Isolation, maintenance and staining of mouse intestinal organoids has been described previously (49, 50) . 378
Briefly, for isolation, 15 cm of the proximal small intestine was removed and flushed with cold PBS. The 379 intestine was then cut into 5 mm pieces, vigorously resuspended in 5mM EDTA-PBS using a 10ml pipette, and 380 placed at 4ºC on a benchtop roller for 10 minutes. This was then repeated for a second time for 30 minutes. containing 10 U/ml DNAse I (Roche, 04716728001), and filtered sequentially through 100µm and 70µm filters. 384 1ml FBS (final 5%) was added to the filtrate and spun at 1200 RPM for 4 minutes. The purified crypts were 385 resuspended in basal media and mixed 1:10 with Growth Factor Reduced Matrigel (BD, 354230). 40l of the 386 resuspension was plated per well in a 48 well plate and placed in a 37ºC incubator to polymerize for 10 minutes. 387 250µl of small intestinal organoid growth media (Basal Media containing 50 ng/mL EGF (Invitrogen 388 PMG8043), 100ng/ml Noggin (Peprotech 250-38), and 500 ng/mL R-spondin (R&D Systems, 3474-RS-050, or 389 from conditioned media) was then laid on top of the Matrigel. Where indicated, dox was added to experiments at 390 500 ng/ml. 391
For sub-culture and maintenance, media was changed on organoids every two days and they were passaged 1:4 392 every 5-7 days. To passage, the growth media was removed and the Matrigel was resuspended in cold PBS and 393 transferred to a 15ml falcon tube. The organoids were mechanically disassociated using a p1000 or a p200 394 pipette and pipetting 50-100 times. 7 ml of cold PBS was added to the tube and pipetted 20 times to fully wash 395 the cells. The cells were then centrifuged at 1000 RPM for 5 minutes and the supernatant was aspirated. They 396 were then resuspended in GFR Matrigel and replated as above. For freezing, after spinning the cells were 397 resuspended in Basal Media containing 10% FBS and 10% DMSO and stored in liquid nitrogen indefinitely. 398
Organoid transfection 399
Murine small intestinal organoids were cultured in transfection medium containing CHIR99021 (5M) and Y-400 27632 (10µM) for 2 days prior to transfection. Single cells suspensions were produced by dissociating organoids 401 with TrypLE express (Invitrogen #12604) for 5 min at 37°C. After trypsinization, cell clusters in 300l 402 transfection medium were combined with 100l DMEM/F12-Lipofectamine2000 (Invitrogen #11668)-DNA 403 mixture (97ul-2ul-1ug), and transferred into a 48-well culture plate. The plate was centrifuged at 600g at 32°C 404 for 60 min, followed by another 6h incubation at 37°C. The cell clusters were spun down and plated in Matrigel. 405
For selecting organoids with Apc mutants, exogenous R-spondin1 and Noggin were withdrawn 2 days after 406 transfection. 407
Organoid Drug Treatment and Counts 408
Organoids were plated in 100 µl Matrigel (2x 50 µl droplets) in one 12 well and cultured in Advanced 409 DMEM/F12 + EGF media with either DMSO or G007-LK 1uM. Three days after plating 8 brightfield images 410 were taken in a vertical line, approximately the length of one droplet. Images were then compiled in one 411 document, and viable organoids were counted for each condition. Organoids were then passaged either 1:2 or 412 1:1 (based on confluency) and then cultured again in DMSO or G007-LK. Day 7 counts were calculated from 413 brightfield images and multiplied by the passaging factor. 414
415
EdU Flow Cytometry 416
Cytometry Assay Kit (Thermo Fisher, # C10634). Organoids were first incubated with 10 µM EdU for 4 hours 418 at 37˚C. One well of a 12 well plate was broken up by pipetting vigorously 50 times in 1mL PBS, then diluted in 419 5 mL of PBS. Cells were pelleted at 1100rpm x 4 min at 4˚C, then resuspended in 50 µL TrypLE and incubated 420 at 37˚C for 5 mins. 5 mL of PBS was then added to inactivate the TrypLE, and cells were pelleted. Cells were 421 resuspended in 250 µL of 1% BSA in PBS, transferred to a 1.7 mL tube, and then pelleted at 3000rpm x 4 min. 422 Cells were then resuspended in 100 µL Click-iT™ fixative, and processed as instructed in the Click-iT™ Plus 423
EdU protocol (starting with Step 4.3). Wash and reaction volumes were 250 µL. 424
Animal studies 425
Production of mice and all treatments described were approved by the Institutional Animal Care and Use 426 Committee (IACUC) at Weill Cornell Medicine (NY), under protocol number 2014-0038. ES cell-derived mice 427 were produced by blastocyst injection and animals were either maintained on a mixed C57B6/129 background 428 for experimental breeding or backcrossed to C57Bl/6N mice. Progeny of both sexes were used for experiments 429 and were genotyped for specific alleles (Lgr5-GFP-IRES-CreER, CAGs-rtTA, Col1A1, TG-shApc.2235E, TG-430 Ren.713, TG-shTnks1/2-3341-1328 , TG-shTnks1/2-1385 , and Apc Min ) using primers described in 431
Supplementary Table 3 San Jose, CA) to create stacks, adjust levels and/or apply false coloring. 466
Tumor Quantification 467
Tumor area in H&E stained slides were quantified using FIJI (Image J). Scanned slides were converted to 8-bit 468 images, one intestinal roll was selected (four rolls per mouse), and an Over/Under threshold was set to capture 469 only cells. The total intestinal area was measured using the 'Measure' feature, and then tumors were then 470 identified, manually traced, and measured. All of the tumor areas were summed, then the ratio of total tumor 471 area: total intestinal area was calculated to determine the Tumor Area for each mouse. Immunofluorescent 472 images of BrdU/DAPI positive tumors were analyzed using FIJI. Images from each channel were exported as 473 separate .tif files, then converted to 16-bit images. The tumor area was traced manually, and the nontumor 474 regions of the image were cleared. A threshold was set to capture only BrdU/DAPI positive cells, then these 475 cells were quantified using the 'Analyze Particles' feature. The ratio of BrdU/DAPI positive cells was then 476 calculated to determine the Fraction of BrdU positive cells within a tumor. IHC images of Alkaline Phosphatase 477 positive tumors were also analyzed using FIJI. Images were converted to 16 bit, and the entire tumor area was 478 traced manually and nontumor regions were cleared from the image. A threshold was then set for the stained 479 areas of the tumor, and the area was quantified using the 'Measure' feature. The total area of the tumor was also 480 measured, and then ratio of Alkaline Phosphatase area: total tumor area was calculated to determine the Fraction 481 of Alkaline Phosphatase Staining. 482 lysed in 30 µl RIPA buffer. Antibodies used for Western blot were: anti-Apc (Millipore, #5535), anti-Axin1 486 (CST, #2087), anti-non-phosphorylated -catenin (CST,), anti-phospho--catenin S33/S37/T41 (CST, #9561), 487 total -catenin (CST, #8480), anti-GSK3 (CST, #9832), anti-actin-HRP (Abcam, #ab49900), anti-Tnks1/2 488 (Santa Cruz, # sc-365897), anti-GFP (Abcam, #ab13970), Anti-α-Tubulin (Millipore Sigma, # CP06). 489
490
Immunoprecipitation 491
To generate 2D cultures, organoids were broken up by pipetting vigorously 50 times, then diluted in 5 mL of 492 Basal Media. Cells were pelleted at 1100rpm x 4 min at 4˚C, then resuspended in 50 µl TrypLE and incubated at 493 37˚C for 5 mins. 5mL of PBS was then added to inactivate the TrypLE, and cells were pelleted. Organoids were 494 resuspended in 2mL Basal Media and plated into one well of a 6 well plate, coated with Rat Tail Collagen I 495 (Thermo Fisher, #A10483-01) at 3g/ml in PBS for 30 min at 37˚C. When confluent (approximately 5 days), 496 2D cell lines were passaged with 500 µl Trypsin, neutralized in 1mL DMEM + 10% FBS, and pelleted. Cells 497 were then resuspended in 2 mL Basal Media and plated on Collagen-coated plates as required. For 498
Immunoprecipitation, cells were then expanded into 2 x 15 cm plates, and when near-confluent, cultured in 499 DMSO or G007-LK (1uM) for 24 hours. Cells were washed once with PBS, then scraped into 1mL IP lysis 500 buffer (10mM Tris 7.4, 150mM NaCl, 0.5mM EDTA, 0.5% NP40 + PPI/PI) and centrifuged at 13000rpm x 10 501 min at 4˚C. 200 µl of lysate was used for the immunoprecipitation using 25ul Protein-A Dynabeads (Thermo 502
Fisher, #10001D) and incubated with Axin1 (1ug, CST, #2087) or IgG (1ug, CST, #2729). Beads were washed 503 (200µl) and eluted (20µl) in IP lysis buffer. 5µl 5X SLB was added to the elution, and samples were denatured 504 at 95˚C for 5 min. 505 506 RNA isolation, cDNA synthesis and qPCR 507 RNA was extracted using TRIzol (Thermo Fisher, #15596018) according to the manufacturer's instructions and 508 contaminating DNA was removed by DNase treatment for 10 mins and column purification (Qiagen RNeasy 509 #74106). cDNA was prepared from 1 µg total RNA using qScript reverse transcription kit (Quantabio, #95047). 510
Quantitative PCR detection was performed using SYBR green reagents (VWR, #101414-288) and specific 511 primers listed in Table S4 . 512
513
RNA sequencing 514
Total RNA was isolated using Trizol, DNAse treated and purified using the RNeasy mini kit (Qiagen, Hilden, 515 Germany). Following RNA isolation, total RNA integrity was checked using a 2100 Bioanalyzer (Agilent 516
Technologies, Santa Clara, CA). RNA concentrations were measured using the NanoDrop system (Thermo 517
Fisher Scientific, Inc., Waltham, MA). Preparation of RNA sample library and RNA-seq were performed by the 518
Genomics Core Laboratory at Weill Cornell Medicine. Messenger RNA was prepared using TruSeq Stranded 519
The normalized cDNA libraries were pooled and sequenced on Illumina NextSeq500 sequencer with single-end 521 75 cycles. 522
RNAseq analysis 523
The quality of raw FASTQ files were checked with FastQC and mapped to mouse reference GRCm38 using 524 STAR two-pass alignment (v2.4.1d; default parameters) (51), and transcript abundance estimates were 525 performed using Kallisto (52), aligned to the same (GRCm38) reference genome. Kallisto transcript count data 526 for each sample was concatenated, and transcript per million (TPM) data was reported for each gene after 527 mapping gene symbols to ensemble IDs using the following R packages ("tximport", tximportData", 528 "ensembldb", and "EnsDb.Mmusculus.v79"). Differential gene expression was estimated using DESeq2 (53). 529
For data visualization and gene ranking, log fold changes were adjusted using the lfcShrink command in 530 DESeq2, to minimize the effect size of poorly expressed genes. GSEA analysis (v3.0) was performed on pre-531 ranked gene sets from differential expression between DMSO and G007-LK-treated groups. We used R (v3. Microinjections were performed by the Memorial Sloan Kettering Cancer Center (MSKCC) mouse transgenic 546 core facility, using C57Bl/6J fertilized zygotes. Viable pups were genotyped by PCR and direct Sanger 547 sequencing. Animals were maintained as heterozygotes by breeding to C57Bl/6N mice. 548 549
Statistical analyses 550
Statistical tests for all data presented here (other than RNAseq) were performed in GraphPad Prism. Detailed 551 results of each test are provided in Table S5 . 
